GlassScriptPhysician profile
Archana Pudur
NPI 1235397688
$6,037.27
in general payments reported to CMS, 2019-2025
30 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $532 · 2021: $991 · 2022: $497 · 2023: $790 · 2024: $1,019 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,893.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,053.65 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $579.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $532.79 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $477.18 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $472.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $431.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.08 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $200.17 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.26 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $193.54 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Exact Sciences Corporation | $192.21 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $168.69 | 2024-2025 | Voquezna |
| Pfizer INC. | $167.39 | 2019-2025 | |
| Astellas Pharma US INC | $152.86 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $116.58 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $115.10 | 2024-2025 | Heplisav-B |
| Fresenius USA Marketing, INC. | $108.97 | 2021 | |
| Amarin Pharma, INC. | $103.63 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $76.17 | 2022-2024 | Quviviq |
| Dexcom, INC. | $70.18 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $62.63 | 2019 | |
| Eisai INC. | $50.03 | 2020-2022 | |
| Abbott Laboratories | $38.49 | 2021-2023 | Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $36.81 | 2021 | |
| Phadia US INC. | $32.38 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $19.89 | 2019 | |
| Boston Scientific Corporation | $17.09 | 2021 | |
| Daiichi Sankyo INC. | $17.04 | 2021 | |
| Allergan, INC. | $15.45 | 2019 | |
| Ethicon US, LLC | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Pudur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.